Table 6 Re-induction therapy.
From: Feasibility of alternating induction and maintenance chemotherapy in pancreatic cancer
Characteristic | |
|---|---|
Patients | 11 |
Treatment cycles, total | 47 |
Treatment cycles, median (range) | 4 (1–7) |
Cycles containing | |
FOLFIRINOX, median (range) | 5 (1–7) |
FOLFOX, median (range) | 4 (2–6) |
Cycles with: | |
Dose reduction | 9 (19%) |
Treatment delay ≥1 week | 16 (34%) |
Treatment time, median (range) | 11.1 weeks (2–30.8) |
